Benitec to Develop CDx for NSCLC Therapy as part of Licensing Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Benitec Biopharma today announced a licensing agreement with the University of New South Wales for use of the university's RNAi technology and to develop a companion diagnostic to identify patients who may develop resistance to chemotherapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.